Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2021-07-29
Product name
Silicon Powder, Enriched Silicon Powder
CAS No.
7440-21-3
Emergency telephone
Infotrac/ +1 800-535-5053
Icons in SDS
Company Information
company name
ISOFLEX USA
e-mail address of the competent person responsible for the Safety Data Sheet
iusa@isoflex.com
Section 2
SECTION 2: Hazards identification
NFPA Rating Emergency Overview: Appearance: White crystalline powder. Flammable solid. Moisture-sensitive. Warning! May cause central nervous system depression. May cause eye and skin irritation. May cause respiratory and digestive tract irritation. Chronic inhalation of crystalline silica may lead to fibrotic lung disease, silicosis or cancer. Target Organs: Central nervous system, lungs
NFPA Ratings
0 = Minimal; 1 = Slight; 2 = Moderate; 3 = Serious; 4 = Severe)
Health hazards
1 Flammability = 0 Reactivity = 0 0 Flammability = 1 Physical Hazard = 1 0 FLAMMABILITY 1
HMIS® ratings
0 = Minimal; 1 = Slight; 2 = Moderate; 3 = Serious; 4 = Severe)
Physical hazards
1
Potential health effects
Eye May cause chemical conjunctivitis and corneal damage Skin May cause irritation and dermatitis; may cause cyanosis of the extremities Ingestion May cause gastrointestinal irritation with nausea, vomiting and diarrhea, ingestion of large amounts may cause CNS depression Inhalation Aspiration may lead to pulmonary edema. Contains crystalline silica, which may lead to respiratory abnormalities and silicosis. Inhalation of dusts causes severe irritation of the upper respiratory tract, gastrointestinal disturbances, albuminuria, gradual loss of weight, and increasing weakness. May cause burning sensation in the chest. Chronic Chronic inhalation of dust may lead to silicosis. May cause silicosis-disabling pulmonary fibrosis characterized by fibrotic changes and miliary nodules in the lungs, dry cough, shortness of breath, emphysema, decreased chest expansion and increased susceptibility to tuberculosis.
Hazard pictograms
F
Hazard statements
11 ________________________________________________________________________________________________